Silexion Therapeutics (NASDAQ:SLXN) Releases Earnings Results, Beats Estimates By $204.70 EPS

Silexion Therapeutics (NASDAQ:SLXN) posted its quarterly earnings results on Thursday. The company reported ($13.70) EPS for the quarter, beating analysts’ consensus estimates of ($218.40) by $204.70, FiscalAI reports.

Silexion Therapeutics Price Performance

SLXN stock opened at $2.51 on Friday. Silexion Therapeutics has a 1 year low of $2.57 and a 1 year high of $777.12. The stock has a market cap of $577,300.00, a price-to-earnings ratio of -0.06 and a beta of -0.30. The company has a 50 day simple moving average of $5.83 and a 200 day simple moving average of $142.68.

Analyst Upgrades and Downgrades

SLXN has been the subject of several analyst reports. Weiss Ratings restated a “sell (e+)” rating on shares of Silexion Therapeutics in a research report on Friday, September 11th. Maxim Group lowered shares of Silexion Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, July 29th. One equities research analyst has rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold”.

Silexion Therapeutics Company Profile

Silexion Therapeutics Ltd. (NASDAQ: SLXN) is an Israel-based clinical-stage biotechnology company developing RNA-based medicines for the treatment of solid tumors driven by mutations in the KRAS oncogene. The company’s technology is designed to selectively silence cancer-causing KRAS mutations while limiting exposure to healthy tissue. Silexion’s lead program, siG12D-LODER, is an investigational RNA interference therapy targeting the KRAS G12D mutation, which is frequently found in pancreatic and other difficult-to-treat cancers.